← All drugs Report issue

zg006

Small moleculeexperimental

Clinical trial activity

9 trials · 2 clinical orgs · 0 marketing orgs

Phase 1

7

Phase 2

7

Phase 3

1

Phase 4

0

Earliest trial started Oct 27, 2023 (NCT05978284)

Timeline

2020s

Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Jan 1, 2025
Earliest Phase 2 Sponsor(trial)
Jan 1, 2025
Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Lymphocyte differentiation antigen CD38INHIBITOR
CD38 inhibitor
- ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) ↗

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT07258121	Phase 1/Phase 2 (Phase 2)	Dec 31, 2025	Henan Medical University, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT07231445	Phase 1	Dec 23, 2025	Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT07189455	Phase 3	Nov 30, 2025	Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT07038096	Phase 1/Phase 2 (Phase 2)	Aug 31, 2025	Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT07024277	Phase 2	Aug 31, 2025	Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06592638	Phase 1	Dec 31, 2024	Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06440057	Phase 1/Phase 2 (Phase 2)	Jun 30, 2024	Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06283719	Phase 1/Phase 2 (Phase 2)	Jun 30, 2024	Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT05978284	Phase 1/Phase 2 (Phase 2)	Oct 27, 2023	Henan Medical University, Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Showing 9 of 9 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Suzhou Zelgen Biopharmaceuticals Co.,Ltd	For profit	9	9	3	2023
Henan Medical University	Academic/Hospital	2	0	1	2023

2 organizations

Page 1 / 1